AXA-UPMC Chair on Alzheimer's disease
Finding new Alzheimer's biomarkers for an earlier diagnosis and therapy
The recently evidenced existence of a silent stage of the disease, with no clinical symptoms expressed, yet biological markers observable, creates opportunities for improving and accelerating diagnoses. The reasonable hope of treatment in a near future urges the need for enabling diagnoses of Alzheimer at a totally asymptomatic stage, particularly for individuals nearing conversion state - when Alzheimer's effects will become evident.
Prof. Hampel and his multi-disciplinary research team in Paris endeavours to characterize the full disease "roadmap" in the brains of living people with all available biological indicators to provide effective early solutions for diagnosis and therapy for affected patients.